BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Analyst Ratings
USA - NASDAQ:BMRN - US09061G1013 - Common Stock
54.48 USD
-0.07 (-0.13%)
54.99 USD
+0.51 (+0.94%)
ChartMill assigns a Buy % Consensus number of 84% to BMRN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 97.37. This target is 78.72% above the current price.
BMRN was analyzed by 34 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about BMRN.
In the previous month the buy percentage consensus was at a similar level.
BMRN was analyzed by 34 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-08 | HC Wainwright & Co. | Initiate | Neutral |
| 2025-08-06 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-05 | UBS | Maintains | Buy -> Buy |
| 2025-07-22 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-05 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-05-02 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-02-24 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-02-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-02-20 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-02-20 | UBS | Maintains | Buy -> Buy |
| 2025-02-20 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-02-20 | B of A Securities | Maintains | Buy -> Buy |
| 2025-02-20 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-20 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-12-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-15 | Wolfe Research | Initiate | Outperform |
| 2024-10-30 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-10-30 | William Blair | Downgrade | Outperform -> Market Perform |
| 2024-10-30 | UBS | Maintains | Buy -> Buy |
| 2024-10-30 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-10-30 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-10-30 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-30 | Baird | Maintains | Neutral -> Neutral |
| 2024-10-30 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2024-10-30 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-10-10 | Raymond James | Reiterate | Outperform |
| 2024-10-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-10-04 | Barclays | Maintains | Overweight -> Overweight |
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
What do analysts expect the price target to be for BIOMARIN PHARMACEUTICAL INC (BMRN)?
34 analysts have analysed BMRN and the average price target is 97.37 USD. This implies a price increase of 78.72% is expected in the next year compared to the current price of 54.48.
How do analysts rate BIOMARIN PHARMACEUTICAL INC (BMRN)?
The consensus rating for BIOMARIN PHARMACEUTICAL INC (BMRN) is 83.5294 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for BMRN stock?
The number of analysts covering BIOMARIN PHARMACEUTICAL INC (BMRN) is 34.